{
    "clinical_study": {
        "@rank": "68860", 
        "arm_group": [
            {
                "arm_group_label": "group B: control bupivacaine group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline."
            }, 
            {
                "arm_group_label": "Group B-peri-DEX:  Peri-neural Dexmedetomidine", 
                "arm_group_type": "Experimental", 
                "description": "Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline"
            }, 
            {
                "arm_group_label": "Group B-sys-DEX:Systemic Dexmedetomidine", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine."
            }
        ], 
        "brief_summary": {
            "textblock": "The duration of sensory block after single dose of long acting local anesthetics is not\n      sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as\n      clonidine have been shown to increase the duration of peripheral nerve block.\n      Dexmedetomidine is a more potent and selective \u03b1-2-adrenoceptor compared to clonidine. To\n      the best of our knowledge, the use of Dexmedetomidine as adjuvant to local anesthetic was\n      not previously reported for femoral nerve block."
        }, 
        "brief_title": "Perineural Dexmedetomidine and Femoral Nerve Block", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Onset and Duration of Sensory and Motor Block of Femoral Nerve,", 
            "Visual Analogue Pain Scores,", 
            "Time to First Request of Rescue Analgesics,", 
            "Total Morphine Consumption in 24 Hours"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all patients with ASA physical status I or II, scheduled for diagnostic knee\n             arthroscopy\n\n        Exclusion Criteria:\n\n          -  Patients who are refusing regional block, patients with diabetic peripheral\n             neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture\n             site, and history of allergic reaction to study medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964040", 
            "org_study_id": "N-38-2013"
        }, 
        "intervention": {
            "arm_group_label": [
                "group B: control bupivacaine group", 
                "Group B-peri-DEX:  Peri-neural Dexmedetomidine", 
                "Group B-sys-DEX:Systemic Dexmedetomidine"
            ], 
            "description": "ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with  0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.\nAfter adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia", 
            "intervention_name": "peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bupivacaine", 
                "Dexmedetomidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "femoral nerve block", 
            "peri-neural dexmedetomidine"
        ], 
        "lastchanged_date": "October 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "02"
                }, 
                "name": "Anesthesia department-faculty of medicine-Cairo University"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Perineural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.", 
        "other_outcome": [
            {
                "description": "The duration of motor block will be defined as: \"the time interval between the end of injection and the complete recovery of motor power of the quadriceps muscle)\".", 
                "measure": "duration of motor block", 
                "safety_issue": "No", 
                "time_frame": "interval between time of injection and complete motor power recover"
            }, 
            {
                "description": "Visual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (12) will be assessed at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively", 
                "measure": "Visual analogue pain scores (resting and dynamic) and Richmond Agitation-Sedation Score (RASS) (", 
                "safety_issue": "No", 
                "time_frame": "2hours post operative and for 24hours"
            }, 
            {
                "description": "The time to the first request of rescue postoperative analgesic will be: \"the time interval between the onset of successful sensory block and the first request to postoperative analgesia\"", 
                "measure": "time of 1st request of rescue analgesia", 
                "safety_issue": "No", 
                "time_frame": "over the poatoperative 24hours"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Higher Education", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Over a period of 30 min after injection of the study medications, a blinded investigator will assess sensory block with pinprick test using a 3-point scale: 0 \u2550 complete loss of sensation, 1 \u2550 partial loss of sensation and 2 \u2550 normal sensation (10). Pinprick test will be done in comparison to the contralateral area at the sensory distribution of the femoral nerve", 
            "measure": "The primary outcome measure of this study will be the change of sensory block over time.", 
            "safety_issue": "No", 
            "time_frame": "intraoperatively every 5 minutes for the first 30 minutes of the operation, then postoperatively every 2 hours for 24hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964040"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Abeer Ahmed", 
            "investigator_title": "lecturer of anesthesia", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The onset time of sensory and motor block will be: \"the time elapsed between the end of injection and the development of complete block (score of 0 at all dermatomes or no movement of the quadriceps muscle.", 
            "measure": "onset of motor and sensory block", 
            "safety_issue": "No", 
            "time_frame": "up to 30 minutes after the end of injection"
        }, 
        "source": "Cairo University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "anesthesia department", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "faculty of medicine", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}